Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07457775 Temozolomide Refractory Soft Tissue Sarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07457775 clinical trial report covering Temozolomide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07459452 Ozureprubart Rhinitis, Allergic, Perennial Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07459452 clinical trial report covering Ozureprubart, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07459166 Fentanyl Citrate Opiate Overdose Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07459166 clinical trial report covering Fentanyl Citrate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260897 Mulberry twig alkaloids Polyendocrine Metabolic Ovarian Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
CTR20260897 clinical trial report covering Mulberry twig alkaloids, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07459504 Amino Acids Metabolic dysfunction-associated steatotic liver disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07459504 clinical trial report covering Amino Acids, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07457164 Teverelix Trifluoroacetate Advanced Prostate Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07457164 clinical trial report covering Teverelix Trifluoroacetate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07458113 Sacituzumab tirumotecan Metastatic Triple-Negative Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07458113 clinical trial report covering Sacituzumab tirumotecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07461831 CD19/CD22-bispecific CAR-T cells(Beijing Tongren Hospital) Large B-cell lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07461831 clinical trial report covering CD19/CD22-bispecific CAR-T cells(Beijing Tongren Hospital), Phase 2, endpoints, sponsor, geography, readout timi
Latest Hotspot
8 min read
NCT07461103 Insulin glargine (Sanofi) Pemphigus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07461103 clinical trial report covering Insulin glargine (Sanofi), Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07458204 Levobupivacaine Hydrochloride Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07458204 clinical trial report covering Levobupivacaine Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
NCT07460362 Lenalidomide Mantle cell lymphoma refractory Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07460362 clinical trial report covering Lenalidomide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
TCTR20260310007 Acetylcysteine Nephrotoxicity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
TCTR20260310007 clinical trial report covering Acetylcysteine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.